NICE limits access to cancer drugs, study confirms

pharmafile | November 10, 2010 | News story | Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta 

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests.

The review, conducted by Bristol-Myers Squibb, produced its analysis from a list of NICE guidance published between 2007 to the end of 2009 using a health technology resource website.

The research showed that in 2007 one in three new drugs was fully recommended for all eligible patients, but that this dropped to just one in 10 by the end of 2009.

BMS’ associate director health economics Maximilian Lebmeier, who led the analysis, said: “The coalition government has stated their commitment to widening access to medicines and we fully support this. 

Advertisement

“The Cancer Drugs Fund is a good interim initiative for cancer patients, but we would like to see wider reform of the HTA system to make it fairer for all patients and widen access to effective medicines.”

Ben Adams

Related Content

NICE backs atogepant for acute migraine treatment

NICE has issued Final Draft Guidance recommending AbbVie’s AQUIPTA (atogepant) as an option for the …

NICE recommends sotatercept for pulmonary arterial hypertension

The National Institute for Health and Care Excellence (NICE) has recommended Winrevair (sotatercept) as a …

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …

The Gateway to Local Adoption Series

Latest content